Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in ALS
NCT06689982Phase 1Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tofacitinib in amyotrophic lateral sclerosis (ALS), sponsored by Beijing Tiantan Hospital. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 180 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06689982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689982.